Understanding immune cells that cause factor VIII antibodies
Defining the Innate Immune Cell Profile of Factor VIII Immunity
Researchers will look at immune cells that trigger harmful antibodies to factor VIII in people with hemophilia A, aiming to find ways to prevent or reduce inhibitor formation.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11323085 on NIH RePORTER |
What this research studies
This project will map which innate immune cells and early immune events lead to neutralizing antibodies against infused factor VIII in people with hemophilia A. Researchers will analyze immune responses to factor VIII to pinpoint the cells involved and the timing of their actions. The team aims to identify cellular targets that could make tolerance treatments safer, faster, or less burdensome. If clear targets emerge, the findings will guide development of targeted immunomodulatory therapies.
Who could benefit from this research
Good fit: Ideal candidates would be people with hemophilia A who currently have inhibitors to factor VIII or are at high risk of developing them, including both children and adults.
Not a fit: People without hemophilia A or those who already tolerate factor VIII without antibodies are unlikely to receive direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could lead to therapies that prevent or eliminate factor VIII inhibitors, reducing bleeding risk and the need for long, intensive immune tolerance treatments.
How similar studies have performed: Traditional immune tolerance induction has worked for some patients over decades, but targeted approaches focused on innate immune cells are relatively new and less well proven.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Batsuli, Glaivy — Stanford University
- Study coordinator: Batsuli, Glaivy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.